GC
FCSC

Guggenheim Capital’s Fibrocell Science Inc. FCSC Stock Holding History

Guggenheim Capital’s Portfolio FCSC Stock Details FCSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-728
Closed -$58K – 3342
2014
Q1 		$58K Buy
+728
New +$56.4K ﹤0.01% 3105

Other funds holding FCSC

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $6.03B AUM 24.5% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Guggenheim Capital's FCSC Position: Q2 2014 in Review

Guggenheim Capital sold out of Fibrocell Science Inc. (FCSC) in Q2 2014, closing a stake of 728 shares — an estimated $58K sold.

Guggenheim Capital first reported a position in FCSC in Q1 2014 and held it in 1 quarter. The position peaked at $58K in Q1 2014. 44 funds tracked by Wall St. Rank hold FCSC as of Q2 2014.

  • Guggenheim Capital reported no remaining Fibrocell Science Inc. position as of Q2 2014 after selling out during the quarter.
  • Guggenheim Capital sold 728 Fibrocell Science Inc. shares in Q2 2014, an estimated $58K.
  • Guggenheim Capital first reported a position in Fibrocell Science Inc. in Q1 2014 and held it in 1 quarter.
  • Guggenheim Capital's Fibrocell Science Inc. position peaked at $58K in Q1 2014.
  • 44 funds tracked by Wall St. Rank held Fibrocell Science Inc. as of Q2 2014.

Based on Guggenheim Capital's 13F filing for Q2 2014, filed 14 Aug 2014.